1. Sasano H, Uzuki M, Sawai T, Nagura H, Matsunaga G, Kashimoto O, Harada N: Aromatase in human bone tissue. J Bone Miner Res. 1997, 12: 1416-1423. 10.1359/jbmr.1997.12.9.1416.
2. Eastell R, Adams A: Results of the 'Arimidex' (anastrozole, A), tamoxifen (T), alone or in combination (C) (ATAC) trial: Effects on bone mineral density (BMD) and bone turnover (ATAC Trialists' Group) [abstract 113PD]. Ann Oncol. 2002, 13: 32-
3. Howell A, on behalf of the ATAC Trialists' Group: Effect of anastrozole on bone mineral density: 2-year results of the 'arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) trial [Abstract 129]. Breast Cancer Res Treat. 2003, 83: S27-
4. Heshmati HM, Khosla S, Robins SP, Geller N, McAlister CA, Riggs BL: Endogenous residual estrogen levels determine bone resorption even in late postmenopausal women [abstract 76]. J Bone Miner Metab. 1997, 12: S121-
5. Harper-Wynne C, Ross G, Sacks N, Salter J, Nasiri N, Iqbal J, A'Hern R, Dowsett M: Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev. 2002, 11: 614-621.